Shares of Akero Therapeutics (NASDAQ:AKRO) have been given a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy rating.
Brokers have set a twelve-month consensus price target of $32.00 for the company and are anticipating that the company will post ($0.57) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Akero Therapeutics an industry rank of 56 out of 255 based on the ratings given to its competitors.
Separately, Zacks Investment Research lowered Akero Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 14th.
Shares of AKRO stock traded up $1.11 during trading hours on Thursday, reaching $20.00. The company had a trading volume of 3,854 shares, compared to its average volume of 65,223. The stock has a fifty day simple moving average of $20.39. Akero Therapeutics has a 12-month low of $16.06 and a 12-month high of $30.30.
Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.13). Equities research analysts forecast that Akero Therapeutics will post -2.72 earnings per share for the current fiscal year.
A number of institutional investors have recently modified their holdings of the stock. Griffin Asset Management Inc. purchased a new position in Akero Therapeutics in the second quarter worth approximately $25,000. Strs Ohio purchased a new position in Akero Therapeutics in the third quarter worth approximately $29,000. Tower Research Capital LLC TRC purchased a new position in Akero Therapeutics in the second quarter worth approximately $26,000. Victory Capital Management Inc. purchased a new position in Akero Therapeutics in the second quarter worth approximately $31,000. Finally, Tiverton Asset Management LLC purchased a new position in Akero Therapeutics in the second quarter worth approximately $54,000. Institutional investors own 37.18% of the company’s stock.
Akero Therapeutics Company Profile
Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.
Recommended Story: What is a blue-chip stock?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.